Evidence map›Paper›PMID 37668932›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2024

Endometrial cancer: predictors and oncological safety of tumor tissue manipulation.

Raquel Quintana-Bertó, Pablo Padilla-Iserte, Víctor Lago, Carmen Tauste, Berta Díaz-Feijoo, Silvia Cabrera, Reyes Oliver-Pérez, Pluvio J Coronado, María Belén Martín-Salamanca, Manuel Pantoja-Garrido and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 1 country.

Raquel Quintana-BertóDepartment of Gynecologic Oncology, La Fe University and Polytechnic Hospital, València, Spain. raquelqb.25@gmail.com.ORCID http://orcid.org/0000-0001-5239-3756
Pablo Padilla-IserteDepartment of Gynecologic Oncology, La Fe University and Polytechnic Hospital, València, Spain.
Víctor LagoDepartment of Gynecologic Oncology, La Fe University and Polytechnic Hospital, València, Spain.
Carmen TausteDepartment of Gynecologic Oncology, Complejo Hospitalario de Navarra, Navarra, Spain.
Berta Díaz-FeijooInstitute Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Silvia CabreraGynecologic Oncology Unit, Gynecology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Reyes Oliver-PérezGynecologic Oncology-Unit, Department of Obstetrics and Gynecology, University Hospital 12 de Octubre, 12 de Octubre Research Institute, Complutense University of Madrid, Madrid, Spain.
Pluvio J CoronadoWomen's Health Institute of the Hospital Clínico San Carlos, IdISSC, University Complutense, Madrid, Spain.
María Belén Martín-SalamancaGynecology Department, Hospital Universitario de Getafe, Madrid, Spain.
Manuel Pantoja-GarridoDepartment of Gynecology and Obstetrics, University Hospital Virgen Macarena, Sevilla, Spain.
Josefa Marcos-SanmartinDepartment of Obstetrics and Gynecology, Dr. Balmis General University Hospital, Alicante, Spain.
Eduardo CazorlaDepartment of Obstetrics and Gynecology, Hospital Universitario de Torrevieja, Alicante, Spain.
Cristina LorenzoDepartment of Obstetrics and Gynecology, Hospital Nuestra Señora de La Calendaria, Santa Cruz de Tenerife, Spain.
José Ramón Rodríguez-HernándezGynaecology and Obstetrics Department, University Hospital Virgen de La Arrixaca, El Palmar, Murcia, Spain.
Fernando Roldán-RivasDepartment of Obstetrics and Gynaecology, Clinico Lozano Blesa Hospital, Zaragoza, Spain.
Juan Gilabert-EstellésDepartment of Obstetrics and Gynecology, University General Hospital of València, València, Spain.
Juan Carlos MuruzábalDepartment of Gynecologic Oncology, Complejo Hospitalario de Navarra, Navarra, Spain.
Antonio CañadaDepartment of Biostatistics, Health Research Institute La Fe, València, Spain.
Santiago DomingoDepartment of Gynecologic Oncology, La Fe University and Polytechnic Hospital, València, Spain.
SEGO Spain-GOG Group
Hospital Universitari i Politècnic La Fe · ESComplejo Hospitalario de Navarra · ESHospital Clínic de Barcelona · ESHospital Clínico San Carlos · ESHospital Clínico Universitario Lozano Blesa · ESHospital General Universitario De Valencia · ESHospital Quirón Torrevieja · ESHospital Universitario de Getafe · ESHospital Universitario Nuestra Señora de Candelaria · ESHospital Universitario Virgen de la Arrixaca · ESHospital Universitario Virgen Macarena · ESLeitat Technological Center · ESUniversidad Complutense de Madrid · ESUniversitat Autònoma de Barcelona · ESUniversitat de Miguel Hernández d'Elx · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe main goal of this study is to assess the impact of tumor manipulation on the presence of lympho-vascular space invasion and its influence on oncological results.

methodsWe performed a retrospective multi-centric study amongst patients who had received primary surgical treatment for apparently early-stage endometrial cancer. A multivariate statistical analysis model was designed to assess the impact that tumor manipulation (with the use of uterine manipulator or preoperative hysteroscopy) has on lympho-vascular development (LVSI) in the final surgical specimen.

resultsA total of 2852 women from 15 centers were included and divided into two groups based on the lympho-vascular status in the final surgical specimen: 2265 (79.4%) had no LVSI and 587 (20.6%) presented LVSI. The use of uterine manipulator was associated with higher chances of lympho-vascular involvement regardless of the type used: Balloon manipulator (HR: 95% CI 4.64 (2.99-7.33); p < 0.001) and No-Balloon manipulator ([HR]: 95% CI 2.54 (1.66-3.96); p < 0.001). There is no evidence of an association between the use of preoperative hysteroscopy and higher chances of lympho-vascular involvement (HR: 95% CI 0.90 (0.68-1.19); p = 0.479).

conclusionWhilst performing common gynecological procedures, iatrogenic distention and manipulation of the uterine cavity are produced. Our study suggests that the use of uterine manipulator increases the rate of LVSI and, therefore, leads to poorer oncological results. Conversely, preoperative hysteroscopy does not show higher rates of LVSI involvement in the final surgical specimen and can be safely used.

Indexed as

Endometrial NeoplasmsHysterectomyFemaleHumansNeoplasm StagingRetrospective StudiesEndometrial cancerHysteroscopyOncological outcomesUterine manipulator

Identifiers

PMID37668932
OpenAlexW4386438468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.